Ovid Therapeutics Inc.
OVID · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 1.11 | 0.02 | -0.01 |
| FCF Yield | -84.63% | -20.20% | -43.24% | 54.67% |
| EV / EBITDA | -0.95 | -3.79 | -1.90 | 0.23 |
| Quality | ||||
| ROIC | -73.40% | -43.90% | -37.20% | 68.36% |
| Gross Margin | 100.00% | 100.08% | 99.98% | 100.00% |
| Cash Conversion Ratio | 2.12 | 0.87 | 1.02 | 0.99 |
| Growth | ||||
| Revenue 3-Year CAGR | -27.78% | -87.66% | -50.80% | – |
| Free Cash Flow Growth | -22.01% | 18.94% | -147.83% | 327.85% |
| Safety | ||||
| Net Debt / EBITDA | 0.20 | 0.19 | 0.52 | -1.51 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -515.78 | 0.00 |